The Polycomb group (PcG) protein, enhancer of zeste homologue 2 (EZH2), has an essential role in promoting histone H3 lysine 27 trimethylation (H3K27me3) and epigenetic gene silencing [1] [2] [3] [4] . This function of EZH2 is important for cell proliferation and inhibition of cell differentiation, and is implicated in cancer progression [5] [6] [7] [8] [9] [10] . Here, we demonstrate that under physiological conditions, cyclin-dependent kinase 1 (CDK1) and cyclin-dependent kinase 2 (CDK2) phosphorylate EZH2 at Thr 350 in an evolutionarily conserved motif. Phosphorylation of Thr 350 is important for recruitment of EZH2 and maintenance of H3K27me3 levels at EZH2-target loci. Blockage of Thr 350 phosphorylation not only diminishes the global effect of EZH2 on gene silencing, it also mitigates EZH2-mediated cell proliferation and migration. These results demonstrate that CDK-mediated phosphorylation is a key mechanism governing EZH2 function and that there is a link between the cell-cycle machinery and epigenetic gene silencing.
The Polycomb group (PcG) protein, enhancer of zeste homologue 2 (EZH2), has an essential role in promoting histone H3 lysine 27 trimethylation (H3K27me3) and epigenetic gene silencing [1] [2] [3] [4] . This function of EZH2 is important for cell proliferation and inhibition of cell differentiation, and is implicated in cancer progression [5] [6] [7] [8] [9] [10] . Here, we demonstrate that under physiological conditions, cyclin-dependent kinase 1 (CDK1) and cyclin-dependent kinase 2 (CDK2) phosphorylate EZH2 at Thr 350 in an evolutionarily conserved motif. Phosphorylation of Thr 350 is important for recruitment of EZH2 and maintenance of H3K27me3 levels at EZH2-target loci. Blockage of Thr 350 phosphorylation not only diminishes the global effect of EZH2 on gene silencing, it also mitigates EZH2-mediated cell proliferation and migration. These results demonstrate that CDK-mediated phosphorylation is a key mechanism governing EZH2 function and that there is a link between the cell-cycle machinery and epigenetic gene silencing.
PcG proteins are important regulators of epigenetic gene silencing [8] [9] [10] and have key roles in developmental patterning, X-chromosome inactivation and stem cell maintenance 5, 6, 11 . Many of the proteins in this family function in two distinct protein complexes termed Polycombrepressive complex 1 (PRC1) and Polycomb-repressive complex 2 (PRC2). PRC2 contains four core subunits of EZH2, EED, SUZ12 and RbAp 48(46) in humans or E(z), esc, Su(z)12 and Nurf55 in flies [1] [2] [3] [4] . EZH2 is the catalytic subunit of PRC2 and contains a SET domain responsible for H3K27me3 [1] [2] [3] [4] . This chromatin mark is commonly associated with silencing of differentiation genes in organisms ranging from plants and flies to humans [8] [9] [10] , suggesting that EZH2 is a master suppressor of cell differentiation.
Many studies also link EZH2 to oncogenesis 7, 12 . Compared with corresponding normal tissues, EZH2 levels are frequently elevated in numerous human cancers, including prostate cancer 7 . The abundance of EZH2 correlates with advanced tumour stage and poor prognosis for the patient 7 and forced expression of EZH2 promotes cancer cell proliferation and migration. Conversely, knockdown of EZH2 by RNA interference inhibits cancer cell proliferation and migration 7, 13 . The role of EZH2 in tumorigenesis may reflect its activity in silencing of tumour suppressor genes, such as p16 INK4A , ADRB2 and DAB2IP [14] [15] [16] . Few studies have been performed to understand how the function of this regulatory protein is itself controlled. EZH2 gene transcription is negatively regulated by the tumour suppressor protein, RB, and the microRNA, miR-101 (refs 13 and 17) . Akt phosphorylates EZH2 at Ser 21 and inhibits its methyltransferase activity 18 . However, it is unclear how the function of EZH2 is positively regulated, and maintained, in proliferative cells.
EZH2 expression and activity are higher in proliferating, rather than fully differentiated, cells and tissues 17, 19, 20 . Accordingly, EZH2 has a crucial role in the maintenance of stem cell pluripotency and suppression of cell differentiation 6, 11, 21 . As EZH2 commonly functions in highly proliferative cells that have high CDK activities, we hypothesized that EZH2 might functionally interact with CDKs in proliferative cells. Indeed, EZH2 harbours one perfectly matched (Thr 350) and two imperfectly matched (Thr 421 and Thr 492) CDK phosphorylation motifs (K(R)S(T) PXK(R), where X is any residue 22 ; Supplementary Information, Fig. S1a ). To assess phosphorylation by CDKs, GST fusions of the amino terminus (amino-acid residues 1-559) and carboxy terminus (amino-acid residues 560-741) of EZH2 were used in in vitro protein-kinase assays. The EZH2 N-terminal fragment was phosphorylated by the CDK1-cyclin B1 complex, but the C-terminal fragment was not (Fig. 1a) . As expected, histone H1B, a known CDK1 substrate, was readily phosphorylated in these assays, whereas no phosphorylation of the control glutathione S-transferase (GST) protein was observed (Fig. 1a) . Mutation of Thr 350 to alanine (T350A) resulted in approximately 60% reduction in phosphorylation of the N-terminal EZH2 fragment mediated by CDK1 (Fig. 1b) . In contrast, approximately 30% or no reduction in phosphorylation was observed when T421A and T492A mutants were used as substrates (Fig.  1b) . This suggests that Thr 350 in EZH2 is the major site phosphorylated by the CDK1-cyclin B1 complex in vitro. Further analysis showed that CDK2-cyclin E and CDK2-cyclin A, but not CDK6-cyclin D1, can also phosphorylate EZH2, and that this phosphorylation is largely or completely abolished by the T350A mutation (Fig. 1c) . These data indicate that the EZH2 protein can be specifically phosphorylated at the Thr 350 residue by different CDKs in vitro. Notably, this residue is present in a consensus CDK phosphorylation motif that is evolutionarily conserved from fruit flies to humans ( Fig. 1d ; although the putative CDK site in the fruitfly homologue of EZH2 is imperfectly matched with the CDK consensus motif there is a similar motif in the mitosis regulatory protein, nucleophosmin (NPM or B23) that has been shown to be phosphorylated by CDK1; ref. 30) .
To determine whether CDK1 and CDK2 can phosphorylate EZH2 at Thr 350 in vivo, an antibody specific to phosphorylated Thr 350 (anti-Thr 350 -P) was raised and purified. The antibody reacted with wild-type but not EZH2 T350A in both 293T (Fig. 2a) and prostate cancer LNCaP cells ( Supplementary Information, Fig. S1b ). This reaction was blocked by a peptide containing the phosphorylated Thr 350, but not by the corresponding nonphosphorylated peptide ( Supplementary  Information, Fig. S1c ). Treatment of cellular proteins with λ protein phosphatase completely abolished the reaction of this antibody with EZH2 ( Fig. 2b) , confirming that the anti-Thr 350-P antibody is specific to phosphorylated Thr 350. Ectopic expression of CDK1-cyclin B1 or CDK2-cyclin E substantially increased Thr 350 phosphorylation of both endogenous and exogenous wild-type EZH2, but not EZH2 T350A , in LNCaP cells ( Fig. 2c and Supplementary Information, Fig. S1b GST  WT  T350A  GST  WT  T350A  GST  WT  T350A   T421A  T492A  GST  WT  T350A  T421A  T492A   250   150   100   75   50 Supplementary Information, Fig. S6a. nature cell biology VOLUME 12 | NUMBER 11 | NOVEMBER 2010CDK2, and this effect was enhanced by further treatment with the CDK inhibitor, roscovitine (Fig. 2d) . Thr 350 phosphorylation of both endogenous and ectopically expressed EZH2 in 293T cells was confirmed by mass spectrometry analysis ( Fig. 2e and Supplementary Information, Fig. S1d and S1e). Furthermore, Thr 350-phosphorylated EZH2 was invariably co-localized with the proliferation marker Ki-67 in human prostate tumours (Fig. 2f) . We also found that CDK1 and CDK2 interact with EZH2 in vitro and in vivo ( Supplementary Information, Fig. S2 ). These data indicate that CDKs can phosphorylate EZH2 at Thr 350 under various physiological and pathological conditions.
The biological function of EZH2 is primarily reflected by its global repression of gene transcription 7, 11 . Thus, we performed microarray analysis to gain molecular insights into the effect of EZH2 23 , and treatment of cells with the HDAC inhibitor trichostatin A (TSA) blocks EZH2-mediated gene silencing 7, 23 . Therefore, as a positive control, we also performed microarray analysis of LNCaP cells treated with TSA. As demonstrated in Figure  3a (lanes 2 and 3) , a large set of genes were transcriptionally derepressed by EZH2 knockdown and repressed again in cells with the restored expression of wild-type EZH2. Consistent with the role of HDACs in concert with the PRC2 complex 7, 23 , inhibition of HDACs by TSA also 
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Control vector v5-CDK1 and v5-cyclin B1 v5-CDK2 and v5-cyclin E Flag-p21 The HOXA9 gene is a well-studied EZH2 repression target 1, 18, 24 . To determine whether EZH2 phosphorylation at Thr 350 affects HOXA9 expression, endogenous EZH2 was knocked down or restored by ectopic expression of siRNA-resistant wild-type EZH2 or EZH2 T350A using the strategy shown in Figure 3a and Supplementary Information, Figure S3b . As expected, knockdown of endogenous EZH2 resulted in an increase in HOXA9 expression in LNCaP cells (Fig. 3b, left) . HOXA9 expression was repressed again by restored expression of wild-type EZH2. However, this effect was substantially compromised by the expression of EZH2 T350A (Fig. 3b, left) . Overexpression of CDK2-cyclin E and CDK1-cyclin B1 also repressed HOXA9 gene expression (Fig. 3c) . This effect was abrogated by EZH2 knockdown (Fig. 3c) . Moreover, silencing of endogenous CDK1 and CDK2 increased expression of HOXA9 (Fig. 3d) . No additive effect on HOXA9 expression was observed in cells where CDK1, CDK2 and EZH2 were knocked down (Fig. 3d) . Thus, these data suggest that CDK-mediated Thr 350 phosphorylation on EZH2 is important for its regulation of HOXA9 expression.
Consistent with the fact that EZH2 is a strong promoter of cell proliferation and migration and a master repressor of cell differentiation 7, 11, 17, 21, 25, 26 , our microarray analysis revealed that many genes important for cell growth and differentiation are affected by EZH2 Thr 350 phosphorylation. Knockdown of EZH2 increased DAB2IP expression in LNCaP cells, consistent with previous reports that the putative tumour suppressor gene DAB2IP (which has a role in cancer cell proliferation and metastasis) is a EZH2 target 14, 27 (Fig.  3b, right) . This increase was diminished by restored expression of wild-type EZH2 but not the EZH2 T350A mutant (Fig. 3b, right) . In addition to HOXA9, many other key developmental regulators, including transcription factors in the HOX, FOX and SOX families, are known targets of PRC2 11 . Our microarray data demonstrated that Thr 350 phosphorylation is important for EZH2-mediated repression of many of these genes ( Supplementary  Information, Fig. S3f and S3g). These data indicate that Thr 350 phosphorylation of EZH2 is important for its repression of genes either mediating differentiation or blocking cell proliferation and migration.
EZH2-promoted gene silencing is mediated primarily by its function in catalysing H3K27me3 in the promoters of its target-genes 1, 18, 24 . Consistently, chromatin immunoprecipitation (ChIP) analysis in LNCaP cells demonstrated that knockdown of EZH2 decreased the level of H3K27me3 in the promoters of HOXA9 and DAB2IP (Fig. 4a, b) . This effect was largely reversed by restored expression of wild-type EZH2, but not the EZH2 T350A mutant (Fig. 4a, b) . Next, we assessed whether Thr 350 phosphorylation directly affects the enzymatic activity of EZH2. In vitro histone methyltransferase (HMTase) assays were performed using PRC2 complexes that were either immunoprecipitated from mammalian cells or reconstituted from proteins isolated after baculovirus-mediated expression in insect Sf9 cells. Surprisingly, no difference in HMTase activity was detected in vitro between wild-type EZH2 and the EZH2 T350A mutant ( Supplementary Information, Fig. S4a Supplementary Information, Fig. S4c and S4d) . Thus, the impact of EZH2 Thr 350 phosphorylation on H3K27me3 levels in target-gene promoters (Fig. 4b ) cannot be attributed to changes in stability, formation or intrinsic HMTase activity of PRC2. We performed ChIP assays to test for changes in PRC2 targeting. Indeed, the binding of EZH2 T350A to the promoters of HOXA9 and DAB2IP was much lower, compared with wild-type EZH2 (Fig. 4c, d ). These data suggest that EZH2 Thr 350 phosphorylation may affect PRC2 recruitment to its target loci in cells.
Previous studies demonstrated that EZH2 is frequently overexpressed in advanced human prostate cancers, and that ectopic expression of EZH2 promotes proliferation of immortalized RWPE-1 prostate epithelial cells and PC-3 prostate cancer cells 7 , two cell-lines that express relatively low levels of endogenous EZH2 ( Supplementary Information, Fig. S5a) . Consistent with those studies, ectopic expression of wild-type EZH2 markedly augmented growth of RWPE-1 cells (Fig. 5a) . However, EZH2-stimulated proliferation of RWPE-1 cells was largely attenuated by the T350A mutation (Fig. 5a ). This attenuation was not because of differences between levels of the wild-type and mutated EZH2 proteins (Fig. 5a, inset) . A similar result was obtained in PC-3 cells ( Supplementary Information, Fig. S5b ). Consistent with these observations, we demonstrated using soft-agar assay that ectopic expression of wild-type EZH2 markedly enhanced anchorageindependent growth of 22Rv1 prostate cancer cells (Fig. 5b) . However, this effect was largely diminished in cells infected with lentiviruses expressing the EZH2 T350A mutant (Fig. 5b) , although wild-type and mutated EZH2 proteins were expressed at comparable levels ( Supplementary Information, Fig.  S5c ). In addition to cell proliferation, EZH2 also promotes cell migration 13, 28 . Thus, we performed wound healing assays to determine whether Thr 350 phosphorylation affects the role of EZH2 in cell migration. Similarly to the previous report 13 , expression of wild-type EZH2 significantly accelerated migration of RWPE-1 cells (Fig. 5c, d) . However, the T350A mutation largely diminished EZH2-promoted migration in this cell line (Fig. 5c, d) . Thus, Thr 350 phosphorylation contributes to the tumour-promoting functions of EZH2, including proliferation and migration. , and cultured in medium with agar for two weeks. Scale bar, 300 μm. Clones with the diameter larger than 300 μm in ten randomly selected fields were counted (graph, inset). Our data demonstrate that CDKs function as important positive regulators of EZH2 through phosphorylation at the Thr 350 residue. Notably, the motif containing Thr 350 is evolutionarily conserved, suggesting that this regulatory mechanism could be functional in other organisms. Although the T350A mutation does not alter the intrinsic HMTase activity of PRC2 as assessed by in vitro assays using HeLa polynucleosomes as a substrate, Thr 350 phosphorylation not only affects H3K27me3 levels in the EZH2 target loci examined, it also regulates the global effect of EZH2 on gene silencing in different cell types. Consistent with these observations, ablation of Thr 350 phosphorylation diminishes the binding of EZH2 to its target loci in cells. Thus, our data identify CDK1-and CDK2-mediated Thr 350 phosphorylation as an important mechanism in control of EZH2-mediated epigenetic gene silencing in mammalian cells.
The function of EZH2 is essential for silencing of differentiation factors, thereby making key contributions to maintenance of stem cell pluripotency 6, 11, 21 . We demonstrate that CDK phosphorylation is important for EZH2-mediated silencing of developmental regulators, such as members of the HOX, FOX and SOX families ( Fig. 3 and Supplementary  Information, Fig. S3f, g ) that drive cell differentiation. Thus, CDK phosphorylation may augment the role of EZH2 in inhibiting these transcription factors and reinforce continued proliferation over differentiation. On cell cycle exit at certain stages of development, CDK stimulation of EZH2 would probably decline, which might facilitate desilencing of EZH2 targets and cell differentiation.
In addition to its role in repression of cell differentiation, EZH2 is also important for oncogenesis by regulating cancer cell proliferation and migration 7, 15, 17 . We provide evidence that Thr 350 phosphorylation is essential for these functions of EZH2 in prostate cancer cells. Because CDK activity is often elevated in human cancers 29 , our data suggest that aberrant activation of CDKs may contribute to the aggressive phenotype of tumours by phosphorylating and maintaining the oncogenic and gene-silencing functions of EZH2. This regulatory node may serve as a viable therapeutic target to switch off the tumour-promoting functions of EZH2 in human cancers. , EZH2 T421A and EZH2 T492A were generated by site-specific mutagenesis (Stratagene). Mammalian expression vectors of CDK1 and cyclin B1 were kindly provided by H. Piwnica-Worms 31 (Washington University School of Medicine, USA). v5-tagged expression vectors for the active mutants of CDK1 and CDK2, and cyclin B1 and cyclin E were described previously 22, 32 . The N-terminal (amino-acid residues 1-559) and C-terminal (amino-acid residues 560-741) fragments of EZH2 were subcloned into pGEX-4T-1 vector (GE Healthcare) for production of GST-EZH2 fusion recombinant proteins. Amino-acid substitution mutants of the GST-tagged EZH2 N-terminal fragment were generated by PCR-based mutagenesis. Baculovirus expression vectors for mouse Ezh2 (Enx-1) and human EED, SUZ12 and RbAp48 were generated by inserting full-length open reading frames of indicated cDNAs into pFastBac1 vector, as previously described 4 . Expression vector for p27 KIP1 was described previously 33 and plasmid for Flag-tagged p21 WAF1 was purchased from Addgene. The lentiviral expression vectors for GFP (green fluorescent protein; control), wild-type EZH2 and the EZH2 T350A mutant were constructed by subcloning corresponding cDNAs into the bidirectional vector as described 34, 35 . Purified recombinant GST-CDK1, GST-CDK2, GST-cyclin B1, GST-cyclin E and histone H1B were obtained from Cell Signaling Technology.
METHODS
Immunoprecipitation, western blotting and antibodies. Protein immunoprecipitations were carried out using an immunoprecipitation kit (Roche Applied Science) as previously described 22 , and western blotting was performed as previously described 22 . A polyclonal antibody against the phosphorylated EZH2 at the Thr 350 residue was raised by immunizing rabbits with the phosphorylated human EZH2 peptide (AERIKpTPPKRPG), and purifying the antibody over a peptide-affinity column (Thermo scientific). Other antibodies are as follows: anti-CDK1, anti-cyclinB1, anti-EZH2, anti-histone H3 (Cell Signaling Technology); anti-CDK2, anti-p21
, anti-Erk2 (Santa Cruz Biotechnology), antiH3K27me3 (Millipore), anti-v5 (Invitrogen) and anti-Ki67 (Dako). Antibodies used for western blotting were diluted 1:1,000 and those used for immunofluorescent chemistry were diluted 1:500.
In vitro kinase assay. Kinase assays were carried out in the presence of [γ-32 P] ATP by using an in vitro kinase buffer system from Cell Signaling Technology as previously described 22 . Briefly, recombinant CDK and cyclin complexes were incubated with various substrates at 30 °C for 45 min, and the reaction samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography. Photoshop software was used to quantify the intensity of each band.
Mass spectrometry, database searching and phosphorylation site localisation.
A micro-capillary liquid chromatography-tandem mass spectrometry (LC-MS/ MS) analysis of EZH2 protein samples was performed with an LTQ-Orbitrap mass spectrometer (ThermoFinnigan) by the Taplin Mass Spectrometry Facility at Harvard Medical School (https://gygi.med.harvard.edu/index.html) as previously described 36 . The product ion spectra generated by LC-MS/MS were searched against the National Center for Biotechnology Information (NCBI) databases for exact matches using the SEQUEST algorithm. The modification of 79.9663 mass units to serine, threonine and tyrosine was included in the database searches to determine phosphopeptides. Each phosphopeptide that was determined by the SEQUEST program was also manually inspected to ensure confidence.
Cell culture, transfection and lentiviral infection. LNCaP, PC-3, DU145, Rf and C4-2 prostate cancer cells were cultured in RPMI 1640 medium (Mediatech) containing 10% fetal bovine serum (FBS) (Hyclone). The prostate cancer cell line 22Rv1 and the immortalized prostate epithelial cell line BPH1 were cultured in RPMI 1640 medium supplemented with 5% FBS. The prostate cancer cell line LAPC-4 was grown in IMEM supplemented with 15% FBS. BJ, 293T and NIH 3T3 cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% FBS. RWPE-1 cells were cultured in keratinocyte serumfree medium supplied with recombinant human EGF (Invitrogen). Transfections were performed by electroporation using an Electro Square Porator ECM 830 (BTX) or by using Lipofectamine 2000 (Invitrogen). Approximately 75-90% transfection efficiencies were routinely achieved. Lentiviral infection was performed as described 35 . Roscovitine (30 μM, 12 h) was used to inhibit CDK.
RNA interference. siRNAs against the human EZH2, CDK1 and CDK2 genes and nonspecific control siRNAs were purchased from Dharmacon. The targeting sequences of four EZH2 siRNAs and CDK1 and CDK2 siRNAs are listed in Supplementary Information, Table S1 . siRNA-resistant (SR) wild-type and Thr 350A-mutated EZH2 were generated by site-specific mutagenesis (Stratagene).
Oligonucleotide microarray. LNCaP cells were transfected with EZH2-specific siRNAs and plasmids encoding siRNA-resistant wild-type EZH2 (EZH2   SR   ) and Thr 350A (Thr 350A SR ) mutant and incubated for 60 h or treated with DMSO, roscovitine (10 μM) or TSA (5 μM) for 24 h and then harvested for RNA isolation. Total RNA (2 μg) from all samples was prepared using the RNeasy Mini Kit (Qiagen). Synthesized cDNAs were hybridized to Affymetrix Human Genome U133 plus 2.0 microarrays (Santa Clara) at the microarray facility at BioMedical Genomics Center at the University of Minnesota. The data were normalized and analysed by dChip Software 37 . For BJ cells, lentivirus vectors were used to express GFP (control) or siRNA-resistant wild-type EZH2 (EZH2 SR ) or T350A (T350A SR ) mutant. At 96 h after transduction, EZH2-specific or control siRNAs were transfected into BJ cells for 60 h. Total RNA (2 μg) from all triplicate samples was prepared using the RNeasy Mini Kit (Qiagen). cDNA was synthesized and hybridized to HumanHT-12 v4 Expression BeadChip (Illumina) in the microarray facility at the University of Minnesota. Hierarchical clustering was performed using the Genesis software in both studies 38 . Microarray profiling data were deposited in the GEO database (http:// www.ncbi.nlm.nih.gov/geo/, accession numbers GSE20433 and GSE22427).
Real-time RT-PCR.
Total RNA was isolated from cells and cDNA was synthesized using the Super-Script kit from Invitrogen. Two-step real-time polymerase chain reaction (PCR) was performed using the SYBR Green Mix (BioRad) and an iCycler iQTM detection system (BioRad) according to manufacturer's instructions. Both forward and reverse primers were used at a final concentration of 200 nM. The primer sequences used for PCR are described in Supplementary Information, Table S2 . The expression of GAPDH gene in each sample was used as an internal control.
In vitro HMTase assay. The HMTase assay was modified from the method published previously 2, 4, 18 . Immunoprecipitated proteins from transfected 293T cells, or proteins expressed and purified from insect Sf9 cells and HeLa polynucleosomes, were added to the HMTase reaction buffer (12 mM Hepes at pH 7.9, 0.24 mM EDTA, 12% glycerol, 4 mM DTT, 2.5 mM MgCl 2 , 0.5-1 μM 3 H-SAM, and 60-110 mM KCl), and then incubated for 60 min at 30 °C. Reactions were stopped with SDS-sample buffer, resolved by 18% SDS-PAGE, and transferred to Immobilon-P (Millipore), sprayed with EN 3 HANCE (NEN) and exposed to film. The immunoprecipitated wild-type and mutated EZH2 proteins were analysed by western blot analysis with an anti-EZH2 antibody, and the insect expressed recombinant PRC2 complexes were visualised by Coomassie blue staining.
Chromatin immunoprecipitation (ChIP) assay. LNCaP cells were transfected with control siRNA, EZH2 siRNA or EZH2 siRNA plus siRNA-resistant wild-type EZH2 or Thr 350A mutant. At 60 h after transfection, cells were crosslinked with 1% formaldehyde and subjected to ChIP assay, as previously described 33 . The ChIP DNA was extracted with a PCR purification kit (Invitrogen) and was subjected to real-time PCR amplification using the primers specific for the H3K27me3 region in the promoters of HOXA9 and DAB2IP genes (Supplementary Information, Table S2 ). The data for the occupation of H3K27me3 are expressed as a ratio of the cycle threshold for the chromatin immunoprecipitation DNA versus the cycle threshold for the input (1%) samples and further normalized to the values in transfected control cells.
Cell proliferation assay. Cell growth was monitored by absorbance using the MTS assay according to manufacturer's instructions (Promega). Briefly, cells were plated in 96-well plates at a density of 800 cells per well. At the indicated times, 20 μl of CellTiter 96R AQ ueous Solution Reagent (Promega) was added to cells, and incubated for 2 h at 37 °C in the cell incubator. Cell growth was measured in a microplate reader at 490 nm.
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Soft-agar colony formation assay. 22Rv1 cells were infected with lentivirus containing GFP (control) or wild-type or T350A-mutated EZH2 (LV-EZH2 or LV-T350A, respectively). At 3 days after infection, 10,000 cells were suspended in 2 ml RPMI 1640 medium containing 10% FBS and 0.3% agarose, and were then plated over a layer of solidified RPMI 1640 medium containing 10% FBS and 1% agarose in 6-well plates. When the agarose-containing cells were solidified, 2 ml of RPMI 1640 medium containing 10% FBS was added to cover the agarose. Plates were incubated at 37 °C and the medium was changed every 2 to 3 days for 2 weeks before colonies were photographed and counted.
Wound healing assay. RWPE-1 cells transiently transfected with EZH2, EZH2 T350A and control vectors were grown to confluency. Artificial wounds were created on the cell monolayer. Migrated cells and wound healing were visualised at 0, 24, 48 and 72 h.
Tumour specimens, immunofluorescent chemistry and confocal microscopy. Twelve cases of prostate tumours were selected from the surgical pathology files at the University of Minnesota Hospital (Fairview) from patients who had undergone radical prostatectomy between 1996 and 2008. The distribution of Gleason scores was as follows: Gleason 7 (eight cases), Gleason 8 (two cases), and Gleason 9 (two cases). This study was approved by the Institutional Review Board of the University of Minnesota. Sections (5 μm) were cut from formalin-fixed paraffin-embedded tissues. Tissues were deparaffinised and rehydrated, followed by 0.3% H 2 O 2 treatment and several washes with 1 × PBS. Slides were subjected to immunofluorescent chemistry as previously described 22 . Cells or tissue sections were analysed with a laser-scanning microscope LSM510. Table  S1 ). At 40 h after transfection, cells were harvested and cell lysates were subjected to western blot analysis with an anti-EZH2 antibody. si-EZ4 was chosen for subsequent experiments. (b) Knockdown of endogenous EZH2 and restored expression of wild-type and T350A-mutated EZH2. LNCaP cells were co-transfected with si-EZ4 with or without siRNA-resistant EZH2 plasmids as indicated. At 60 h after transfection, cells were harvested for analyses of western blot, or oligo microarray (Fig. 3a) , ChIP assays ( Fig. 4a and 4b ) and real-time RT-PCR (Fig. 3b). (c, d) The effect of T350 phosphorylation of EZH2 on its repression of downstream target genes in normal human BJ fibroblasts. BJ cells were transducted with lentivirus containing GFP (control, LV-C) or wild type or T350A mutated EZH2 (LV-EZH2 or LV-T350A, respectively) for 96 h. Then cells were transfected with control siRNA (si-C) or EZH2 siRNA (si-EZ4) by electroporation. At 60 h after transfection, cells were harvested for western blot analyses (c). Hierarchical clustering of genes (represented by 10,314 probe-sets) exhibiting expression differences among the conditions as indicated in (d). Red and green represent upregulation and downregulation, respectively, relative to the reference samples (si-C). The overall fold changes in expression of EZH2 target genes mediated by EZH2 knockdown in BJ cells are lower than those in LNCaP cells (Fig. 3a) , which is consistent with previous reports that EZH2 activity is much higher in cancerous cells than in normal cells 1 .
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